Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 17/20 | 0.72 |
| ▸ | EP300 | Q09472 | 1/20 | 0.68 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.68 |
| ▸ | CSF1R | P07333 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17797949 | 0.90 | BRD4 (0.59) | BRD4EP300CREBBPCSF1RLMNA | |
| SCHEMBL17798087 | 0.90 | BRD4 (0.58) | BRD4EP300CREBBPCSF1R | |
| SCHEMBL17798081 | 0.87 | BRD4 (0.56) | BRD4EP300CREBBPCSF1RLMNA | |
| SCHEMBL23682894 | 0.84 | BRD4 (1.00) | BRD4EP300CREBBPKCNH2 | |
| SCHEMBL29921057 | 0.82 | BRD4 (0.74) | BRD4EP300CREBBP | |
| SCHEMBL17798075 | 0.82 | BRD4 (0.74) | BRD4EP300CREBBP | |
| SCHEMBL16347410 | 0.81 | BRD4 (0.58) | BRD4EP300CREBBPCSF1R | |
| SCHEMBL29920804 | 0.81 | BRD4 (0.58) | BRD4EP300CREBBPCSF1R | |
| SCHEMBL17798103 | 0.76 | BRD4 (0.59) | BRD4EP300CREBBP | |
| SCHEMBL29920806 | 0.76 | BRD4 (0.59) | BRD4EP300CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10772892-B2 | Bicyclic bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2020-09-15 | — | — | US | claimed |
| EP-3674300-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | Zenith Epigenetics Ltd. (CA) | 2020-07-01 | — | — | EP | claimed |
| US-20160159801-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. | 2016-06-09 | — | — | US | claimed |
| EP-3674300-B1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD (CA) | 2022-10-12 | — | — | EP | disclosed |
| US-11446306-B2 | Bicyclic bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2022-09-20 | — | — | US | disclosed |
| CN-109939113-B | Bicyclic bromodomain inhibitors | 恒翼生物医药科技(上海)有限公司 | 2022-02-15 | — | — | CN | disclosed |
| US-20210177855-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD. (CA) | 2021-06-17 | — | — | US | disclosed |
| US-20210177855-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD. (CA) | 2021-06-17 | — | — | US | disclosed |
| US-10772892-B2 | Bicyclic bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2020-09-15 | — | — | US | disclosed |
| EP-3674300-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | Zenith Epigenetics Ltd. (CA) | 2020-07-01 | — | — | EP | disclosed |
| EP-3010503-B1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD (CA) | 2020-03-11 | — | — | EP | disclosed |
| US-20170216301-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD. | 2017-08-03 | — | — | US | disclosed |
| US-20170216301-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD. | 2017-08-03 | — | — | US | disclosed |
| US-20170216301-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD. | 2017-08-03 | — | — | US | disclosed |
| US-9663520-B2 | Bicyclic bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-05-30 | — | — | US | disclosed |
| US-9663520-B2 | Bicyclic bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-05-30 | — | — | US | disclosed |
| US-9663520-B2 | Bicyclic bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-05-30 | — | — | US | disclosed |
| US-20160159801-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. | 2016-06-09 | — | — | US | disclosed |
| US-20160159801-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. | 2016-06-09 | — | — | US | disclosed |
| US-20160159801-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10772892-B2 | Bicyclic bromodomain inhibitors | BRD4, BRD3, BRD2 | BRD4 1/4885EP300 15/4885CREBBP 24/4885 |
| US-11446306-B2 | Bicyclic bromodomain inhibitors | BRD4, BRD3, BRD2 | BRD4 1/4885EP300 15/4885CREBBP 24/4885 |
| US-20170216301-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | BRD4 1/4885EP300 11/4885CREBBP 23/4885 |
| US-20210177855-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | BRD4 1/4885EP300 11/4885CREBBP 23/4885 |
| US-20160159801-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | BRD4 1/4885EP300 11/4885CREBBP 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.